Get the Stockscreener App
39.44
0.68%
0.255
Overview
News
Price History
Option Chain
Financials
Why TEVA Down?
Discussions
Forecast
Stock Split
Dividend History
Teva Pharmaceutical Industries Ltd Adr stock is traded at $39.44, with a volume of 4.24M.
It is up +0.68% in the last 24 hours and up +7.30% over the past month.
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
See More
Previous Close:
$39.18
Open:
$38.84
24h Volume:
4.24M
Relative Volume:
0.80
Market Cap:
$45.99B
Revenue:
$17.53B
Net Income/Loss:
$1.58B
P/E Ratio:
29.30
EPS:
1.3457
Net Cash Flow:
$444.18M
1W Performance:
+0.34%
1M Performance:
+7.30%
6M Performance:
+29.24%
1Y Performance:
+95.18%
1-Day Range:
$38.25
$39.64
1-Week Range:
$38.25
$40.03
52-Week Range:
$18.82
$40.79
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile
Name
Teva Pharmaceutical Industries Ltd Adr
Sector
Phone
972 (3) 914-8213
Address
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
Compare TEVA vs TAK, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.43 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
TAK
Takeda Pharmaceutical Co Adr
|
18.49 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.235 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.27 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
541.01 | 20.39B | 3.17B | 1.29B | 1.01B | 27.09 |
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Overweight |
| Dec-05-25 | Initiated | Scotiabank | Sector Outperform |
| Jun-06-25 | Initiated | Goldman | Buy |
| May-28-25 | Initiated | Truist | Buy |
| May-12-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-10-24 | Upgrade | Argus | Hold → Buy |
| Mar-08-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Feb-12-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-23-24 | Upgrade | Jefferies | Hold → Buy |
| Jan-03-24 | Upgrade | Piper Sandler | Underweight → Neutral |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Nov-27-23 | Upgrade | UBS | Neutral → Buy |
| Jul-06-23 | Upgrade | UBS | Sell → Neutral |
| May-25-23 | Initiated | Morgan Stanley | Equal-Weight |
| May-18-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-19-23 | Downgrade | Jefferies | Buy → Hold |
| Nov-14-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-04-22 | Downgrade | UBS | Neutral → Sell |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Aug-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-14-22 | Resumed | UBS | Neutral |
| May-17-22 | Upgrade | BofA Securities | Underperform → Neutral |
| May-04-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Apr-05-22 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-25-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-27-22 | Downgrade | Argus | Buy → Hold |
| Oct-28-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-04-21 | Downgrade | UBS | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-25-20 | Initiated | Oppenheimer | Perform |
| Aug-06-20 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-27-20 | Resumed | Goldman | Neutral |
| Jun-01-20 | Upgrade | SunTrust | Hold → Buy |
| Apr-24-20 | Resumed | Citigroup | Neutral |
| Apr-06-20 | Upgrade | UBS | Neutral → Buy |
| Feb-24-20 | Downgrade | Edward Jones | Hold → Sell |
| Nov-12-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-17-19 | Upgrade | Gabelli & Co | Hold → Buy |
| Aug-07-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-19-19 | Initiated | Wolfe Research | Peer Perform |
| Jul-15-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-10-19 | Resumed | Credit Suisse | Neutral |
| Jul-05-19 | Upgrade | Argus | Hold → Buy |
| Jun-11-19 | Initiated | Barclays | Underweight |
| Jun-03-19 | Upgrade | Oppenheimer | Perform → Outperform |
| May-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| May-28-19 | Downgrade | UBS | Buy → Neutral |
| Mar-20-19 | Initiated | SunTrust | Hold |
| Mar-07-19 | Resumed | UBS | Buy |
View All
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Latest News
TD Cowen initiates Teva Pharma stock with buy rating on pipeline - Investing.com
Here's Why You Should Add URGN Stock to Your Portfolio Now - Zacks Investment Research
Teva Pharmaceutical Industries Limited (TEVA) stock price, news, quote and history - Yahoo Finance Australia
Teva Pharmaceutical Industries Limited (TEVA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Teva stock hits 52-week high at $39.71 By Investing.com - Investing.com Canada
Teva stock hits 52-week high at $39.71 - Investing.com
TEVA Stock Price and Chart — TASE:TEVA - TradingView
ETFs Investing in Teva Pharmaceutical Industries Limited Sponsored ADR Stocks - TradingView
TEVA Stock Quote Price and Forecast - CNN
Teva plans senior notes offering to refinance existing debt By Investing.com - Investing.com Canada
TEVA Stock Price, Quote & Chart - ChartMill
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers - TradingView
Organon & Co. (OGN) Peer Comparison – Compare with Others - Value Research
Teva announces commitment with Trump administration on Medicaid drug pricing By Investing.com - Investing.com South Africa
Teva Pharma Industries Ltd ADR (TEVA) Peer Comparison – Compare with Others - Value Research
Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy - Sahm
Teva Pharma Industries Ltd ADR (TEVA) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
India Central Nervous System Therapeutic Market Outlook, 2033 - Grand View Research
Teva stock hits 52-week high at 37.84 USD By Investing.com - Investing.com Australia
Teva Pharmaceutical Industries (TEVA) Could Be 10% Undervalued After FDA Accepted Ecopipam NDA - sahmcapital.com
Teva (TEVA) Wins FDA Priority Review For Pediatric Tourette Drug Candidate - Sahm
Teva receives FDA priority review for Tourette drug - grafa.com
Teva Pharmaceutical’s stock is near its yearly high; is it still a buy? - Investing.com Nigeria
TEVA PHARMACEUTICAL INDUSTRIES LTD SEC Filing (Aug 17, 2026) - Stock Titan
Teva stock hits 52-week high at 37.35 USD By Investing.com - Investing.com Nigeria
Teva stock hits 52-week high at 37.35 USD - Investing.com
Moody’s upgrades Teva rating to investment grade on debt cuts By Investing.com - Investing.com Canada
Teva Pharmaceutical Industries (TEVA) Lifts Outlook On Earnings As Valuation Debate Stays Open - Sahm
Teva (TEVA) Is Up 8.8% After Raising 2026 Guidance And Highlighting Innovative Drug Momentum - Sahm
Dear Teva Pharmaceutical Stock Fans, Mark Your Calendars for September 14 - Yahoo Finance
Teva Earnings: Innovation Engine Continues Firing and Supports Our Increased Moat Rating - Morningstar
July 2026's Top Stock Selections Estimated Below Intrinsic Value - Sahm
Teva Pharmaceutical Industries (TEVA) Raises Revenue Guidance, Is The 15% Undervaluation Still There? - Sahm
Earnings call transcript: Teva’s Q2 2026 revenue beats, shares rise premarket - Investing.com
Why Is Teva (NYSE:TEVA) Making NYSE Composite Headlines? - Kalkine Media
Daily Brief Health Care: Apnimed, Chugai Pharmaceutical, Equifax Inc, Royalty Pharma , Startline, Surgery Partners, Teva Pharmaceutical Sp Adr, Thermo Fisher Scientific Inc and more - Smartkarma
Teva Pharmaceutical Industries Limited Sponsored ADR Revenue Breakdown – BX:TEV - TradingView
Does Teva Pharmaceutical Industries (NYSE:TEVA) Still Look Undervalued After A 260% Run? - Sahm
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.49%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):